Literature DB >> 19890651

[Imaging techniques in rheumatology: PET in rheumatology].

D Sandrock1, M Backhaus.   

Abstract

Positron emission tomography (PET) using F-18-fluoro-deoxyglucose (FDG) is suitable for many indications in oncology and can also be used in rheumatology to search for inflammatory foci and benign lesions with increased glucose metabolism in, for example soft tissue and joints (arthritis, vasculitis etc.) and fever of unknown origin. Usually a whole-body scanning technique is used for data acquisition in the search for foci of unknown localization or for the characterization of glucose metabolism of one or more known lesions - also for observation of the effect of, for example pharmacotherapy. Patients are admitted under fasting conditions and acquisition starts 1 h after i.v. injection of FDG with an acquisition time of 30-60 min. The method is sensitive and can measure glucose metabolism in an objective manner, but is not specific for inflammatory diseases (FDG also accumulates in malignant diseases).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19890651     DOI: 10.1007/s00393-009-0546-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  16 in total

1.  [Guidelines for nuclear medicine image presentation].

Authors:  B Knoop
Journal:  Nuklearmedizin       Date:  1999       Impact factor: 1.379

2.  Non-invasive imaging in the diagnosis and management of Takayasu's arteritis.

Authors:  J Andrews; A Al-Nahhas; D J Pennell; M S Hossain; K A Davies; D O Haskard; J C Mason
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

3.  18F-FDG PET and PET/CT in fever of unknown origin.

Authors:  Johannes Meller; Carsten-Oliver Sahlmann; Alexander Konrad Scheel
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

4.  [FDG-PET/CT in oncology. German Guideline].

Authors:  B J Krause; T Beyer; A Bockisch; D Delbeke; J Kotzerke; V Minkov; M Reiser; N Willich
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

5.  PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.

Authors:  L K Griffeth; F Dehdashti; A H McGuire; D J McGuire; D J Perry; S M Moerlein; B A Siegel
Journal:  Radiology       Date:  1992-01       Impact factor: 11.105

Review 6.  [Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin].

Authors:  S N Reske; R Bares; U Büll; A Guhlmann; E Moser; M F Wannenmacher
Journal:  Nuklearmedizin       Date:  1996-04       Impact factor: 1.379

7.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.

Authors:  G Di Chiro
Journal:  Invest Radiol       Date:  1987-05       Impact factor: 6.016

8.  Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.

Authors:  C K Hoh; R A Hawkins; J A Glaspy; M Dahlbom; N Y Tse; E J Hoffman; C Schiepers; Y Choi; S Rege; E Nitzsche
Journal:  J Comput Assist Tomogr       Date:  1993 Jul-Aug       Impact factor: 1.826

9.  Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis.

Authors:  D Blockmans; W Coudyzer; S Vanderschueren; S Stroobants; D Loeckx; S Heye; L De Ceuninck; G Marchal; H Bobbaers
Journal:  Rheumatology (Oxford)       Date:  2008-05-31       Impact factor: 7.580

10.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.

Authors:  Daniël Blockmans; Liesbet de Ceuninck; Steven Vanderschueren; Daniël Knockaert; Luc Mortelmans; Herman Bobbaers
Journal:  Arthritis Rheum       Date:  2006-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.